|
|
Volumn 9, Issue 10, 2010, Pages 754-
|
|
Deal watch: GlaxoSmithKline and Amplimmune join forces on targeting PD1
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AMP 224;
ANTINEOPLASTIC AGENT;
CD137 ANTIGEN;
CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;
PROGRAMMED DEATH 1 LIGAND 1;
PROGRAMMED DEATH 1 RECEPTOR;
UNCLASSIFIED DRUG;
CANCER IMMUNOTHERAPY;
CLINICAL TRIAL;
HUMAN;
IMMUNOMODULATION;
INFECTION;
MERGERS AND ACQUISITIONS;
NEOPLASM;
NONHUMAN;
PRIORITY JOURNAL;
SHORT SURVEY;
T LYMPHOCYTE;
|
|
EID: 84928582572
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd3284 Document Type: Short Survey |
|
Times cited : (3)
|
|
References (0)
|